UB-311
Alzheimer's Disease
Phase 2Active
Key Facts
About Vaxxinity
Vaxxinity is developing a next-generation immunotherapy platform to transform the treatment of chronic diseases and infectious threats. Its core AIM technology uses synthetic peptides to convert the body into its own 'drug factory,' stimulating targeted antibody production with a validated profile across billions of animal health doses and multiple human trials. The company is advancing a pipeline targeting large markets like Alzheimer's, Parkinson's, and COVID-19, with a strategic focus on creating accessible, scalable, and durable medicines that do not require complex frozen logistics.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |